This is a working overview of Synthetic peptide, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-06-01. Anything still debated is marked as such rather than presented as settled.
BPC-157 is a synthetic peptide of fifteen amino acids, written in single-letter code as GEPPPGKPADDAGLV. The sequence corresponds to a partial fragment of a protein isolated from human gastric juice, described in early reports as body protection compound. The number 157 refers to a fragment designation in that work rather than to molecular mass. Initial descriptions appeared in the early 1990s, when the fragment was reported to protect gastrointestinal tissue in animal models. Commercial material is produced by solid-phase peptide synthesis rather than extracted from biological sources.
Laboratory research on this peptide has examined a wide and heterogeneous set of endpoints, including gastric ulcer models, tendon and ligament injury, wound closure, and intestinal inflammation. Most published findings come from rodent studies, and reported effect sizes are often large relative to controls. Because the compound has been tested across many unrelated injury models, the literature is frequently described as unusually broad for a single peptide. A substantial share of this work originates from a small number of research groups, which matters when assessing how widely results have been reproduced.
Most published reports describe experiments in rodents rather than in people. These studies examine outcomes in tendons, ligaments, bone, stomach lining, and intestinal tissue. In rat and mouse models, a frequently reported effect is faster healing or reduced damage. Sample sizes are usually small, and a substantial share of the work originates from a small number of research groups. Independent replication is limited, so how far the findings extend to humans remains an open question.
Proposed mechanisms in the literature involve the nitric oxide system, vascular endothelial growth factor signaling, and epidermal growth factor receptor pathways. Some studies report changes in blood vessel formation or in inflammatory mediators, while others describe interactions with nervous tissue. Much of this evidence rests on molecular markers in cultured cells or animal models. Whether the same pathways operate the same way in humans has not been established. Authors therefore tend to describe mechanisms as hypothetical rather than settled.
| Property | Value | Notes |
|---|---|---|
| Class | Synthetic peptide | Linear, fifteen residues |
| Sequence | GEPPPGKPADDAGLV | Single-letter amino acid code |
| Approximate mass | 1419 Da | Value reported for the free peptide |
| Reported origin | Fragment of a gastric juice protein | Used as the design template |
| Common synonyms | Body protection compound 157; PL 14736 | Naming varies across papers and suppliers |
BPC-157 is a synthetic peptide built from fifteen amino acid residues. Its sequence comes from a larger protein fragment that researchers isolated from human gastric juice and described as a body protection compound. The fragment contains glycine, glutamic acid, five prolines, lysine, alanine, two aspartic acids, leucine, and valine. The number 157 in the name refers to the position of the stretch within the parent protein. Material used in laboratories is manufactured rather than extracted from stomach fluid.
The molecule carries 15 residues, a molar mass near 1419.5 g/mol, and the formula C62H98N16O22. Its structure features a proline-rich central region, a pair of adjacent aspartic acid residues, and no cysteine. The absence of cysteine means no disulfide bonds can form, which simplifies refolding and reconstitution. Suppliers usually ship the material as a freeze-dried powder that appears white to off-white. It dissolves readily in water and in saline solutions.
Published studies on BPC-157 are dominated by animal models. Commonly used endpoints include healing of surgically induced lesions in the stomach, tendon-to-bone attachment after transection, and recovery from experimentally induced vascular or intestinal damage. Many of these reports come from a small number of research groups, and the peptide is often described as acting across a wide range of tissue types. That breadth is itself a point of discussion, since one molecule influencing many unrelated systems is unusual.
Human data are far more limited than animal data. A small number of clinical reports exist, generally with few participants and without the randomization or blinding expected in later-phase trials. No large, independently replicated human trial has appeared in the indexed peer-reviewed literature. Statements about effects in people therefore rest on extrapolation from animal work rather than on direct evidence, and the strength of that extrapolation remains an open question rather than a settled matter.
This defect mobility is the source of most transport phenomena within an ionic crystal, including diffusion and solid state ionic conductivity. When vacancies collide with interstitials (Frenkel), they can recombine and annihilate one another. Similarly, vacancies are removed when they reach the surface of the crystal (Schottky). Defects in the crystal structure generally expand the lattice parameters, reducing the overall density of the crystal. Defects also result in ions in distinctly different local environments, which causes them to experience a different crystal-field symmetry, especially in the case of different cations exchanging lattice sites. This results in a different splitting of d-electron orbitals, so that the optical absorption (and hence colour) can change with defect concentration.
From 1975 to 1980, the Rhodesian government made several attempts to weaponise chemical and biological agents. Members of the security forces contaminated supplies before replacing them in guerrilla caches or planted them in rural stores to be stolen by the guerrillas during raids. They also poisoned water sources along known infiltration routes along the Rhodesian border, forcing their opponents to travel through more arid regions or carry more water during their treks. The chemical agents most used in the Rhodesian chemical and biological warfare (CBW) programme were parathion (an organophosphate insecticide) and thallium (a heavy metal commonly found in rodenticide). The weapons the Rhodesians selected for use also included Vibrio cholerae (causative agent of cholera) and possibly Bacillus anthracis (causative agent of anthrax). They also looked at using Rickettsia prowazekii (causative agent of epidemic typhus), and Salmonella typhi (causative agent of typhoid fever), and toxins such as ricin and botulinum toxin. Biological agents, namely Vibrio cholerae, had some impact on the fighting capability of ZANLA. Some former officers of the Rhodesian Security Forces alleged that anthrax was used covertly during the late 1970s, but this has been disputed. Use of anthracis, ricin, or botulinum toxin was favoured during assassination attempts of prominent guerrilla commanders.
Further adjustments variations on BARAC to produce DIBAC/ADIBO were performed to add distal ring strain and reduce sterics around the alkyne to further increase reactivity. Keto-DIBO, in which the hydroxyl group has been converted to a ketone, has a three-fold increase in rate due to a change in ring conformation. Attempts to make a difluorobenzocyclooctyne (DIFBO) were unsuccessful due to the instability. Problems with DIFO with in vivo mouse studies illustrate the difficulty of producing bioorthogonal reactions. Although DIFO was extremely reactive in the labeling of cells, it performed poorly in mouse studies due to binding with serum albumin. Hydrophobicity of the cyclooctyne promotes sequestration by membranes and serum proteins, reducing bioavailable concentrations. In response, DIMAC (dimethoxyazacyclooctyne) was developed to increase water solubility, polarity, and pharmacokinetics, although efforts in bioorthogonal labeling of mouse models is still in development.
Sources: en.wikipedia.org
=== Nucleation === The original theory from 1927 of nucleation in nanoparticle formation was Classical Nucleation Theory (CNT). It was believed that the changes in particle size could be described by burst nucleation alone. In 1950, Viktor LaMer used CNT as the nucleation basis for his model of nanoparticle growth. There are three portions to the LaMer model: 1. Rapid increase in the concentration of free monomers in solution, 2. fast nucleation of the monomer characterized by explosive growth of particles, 3. Growth of particles controlled by diffusion of the monomer. This model describes that the growth on the nucleus is spontaneous but limited by diffusion of the precursor to the nuclei surface. The LaMer model has not been able to explain the kinetics of nucleation in any modern system.
Other types of atypical work contract include part-time, fixed-term and labour hire staff. First, since the Workplace Relations Act 1996 section 526, awards have been able to provide equal treatment for part-time workers. Part-time employees are often also casual employees and not treated equally regarding holidays and job security, and this has a negative disproportionate impact on women. Second, fixed-term staff are treated unequally compared to permanent staff in that the simple expiry of a fixed term counts as an unchallengeable reason for dismissal, no matter how capriciously or maliciously motivated the reasons are for non-renewal. Third, under the FWA 2009 sections 306C-G there is a limited right to equal treatment for employees contracted through a labour hire firm compared to directly hired employees, after application to the Fair Work Commission. However unlike wealthier OECD countries the right is not automatic, and unavailable for workers of small businesses.
It is known also as simpler's joy or holy herb, or more ambiguously as mosquito plant or wild hyssop. The common name blue vervain is also sometimes used, but also refers to V. hastata. Being the only member of its genus in much of its range, it is also simply known as vervain locally. The common names of V. officinalis in many Central and Eastern European languages often associate it with iron, for example:
Sources: en.wikipedia.org
It is a synthetic fifteen-amino-acid peptide whose sequence matches part of a protein found in human gastric juice. It is made by chemical synthesis, not purified from tissue. The name derives from an early fragment label, not from a molecular weight.
The sequence corresponds to a segment of a naturally occurring gastric protein, so related sequence material exists in the body. The peptide itself as sold and studied is a laboratory-synthesized product. Whether an identical free peptide circulates naturally is not established.
No major regulatory agency has approved it as a medicine for any indication. It appears in research supply channels and, in some jurisdictions, in compounded preparations. Clinical use therefore sits outside standard approved-product pathways, and regulatory status varies by country.
Animal experiments form the bulk of the published record. Rodent models of tendon, ligament, bone, and gut injury are the most common designs. Controlled human trials are rare, which limits confidence in any clinical claim.